0000000000145570

AUTHOR

Giuliani G

showing 5 related works from this author

Heterogeneous impact of an early IFN beta treatment on disability progression in relapsing remitting MS subgroups with differnt baseline clinical pro…

2007

researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

Predictors of definite Multiple Sclerosis in patients with pediatric onset first demyelinating clinical attack

2014

Multiple Sclerosis pediatric onsetSettore MED/26 - Neurologia
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

Definition of criteria and indicators for the prevention of Healthcare-Associated Infections (HAIs) in hospitals for the purposes of Italian institut…

2017

Background. Healthcare-associated infections (HAIs) are an important issue in terms of quality of care. HAIs impact patient safety by contributing to higher rates of preventable mortality and prolonged hospita- lizations. In Italy, analysis of the currently available accreditation systems shows a substantial heteroge- neity of approaches for the prevention and surveillance of HAIs in hospitals. The aim of the present study is to develop and propose the use of a synthetic assessment tool that could be implemented homogenously throughout the nation. Methods. An analysis of nine international and of the 21 Italian regional accreditation systems was conducted in order to identify requirements a…

Process Assessment (Health Care)Cross InfectionProcess Assessment Health CareEnvironmental and Occupational HealthOutcome indicatorsProcess AssessmentHealthcare-Associated Infections (HAIs); Institutional accreditation; Outcome indicators; Patient safety; Performance monitoring; Public Health Environmental and Occupational Health; Infectious DiseasesSettore MED/42 - Igiene Generale E ApplicataHospitalsAccreditationHealthcare-Associated Infections (HAIs); Institutional accreditation; Outcome indicators; Patient safety; Performance monitoring; Cross Infection; Hospitals; Humans; Italy; Accreditation; Process Assessment (Health Care)Health CareHealthcare-Associated Infections (HAIs); Institutional accreditation; Outcome indicators; Patient safety; Performance monitoringInstitutional accreditationPatient safetyHealthcare-Associated Infections (HAIs); Institutional accreditation; Outcome indicators; Patient safety; Performance monitoring; Cross Infection; Hospitals; Humans; Italy; Accreditation; Process Assessment Health CareInfectious DiseasesHealthcare-Associated Infections (HAIs) Patient safety Institutional accreditation Performance monitoring Outcome indicatorsItalySettore MED/33 - Malattie Apparato LocomotoreHumansOutcome indicatorPublic HealthPerformance monitoringHealthcare-Associated Infections (HAIs)
researchProduct